Similar articles

• Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

  Pandha H. Pandha H. Integr Cancer Ther. 2004 Mar;3(1):29-34. doi: 10.1177/1534735404262986. Integr Cancer Ther. 2004. PMID: 15035872 No abstract available.
• Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.

  Parton M, Gore M, Eisen T. Parton M, et al. J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
• Integrative tumor board: metastatic renal cell carcinoma: medical oncology.

  Gupta SK, Vogelzang N. Gupta SK, et al. Integr Cancer Ther. 2004 Mar;3(1):26-9. doi: 10.1177/1534735403261846. Integr Cancer Ther. 2004. PMID: 15035871 No abstract available.
• High-dose interleukin-2 in metastatic renal cell carcinoma.

  Fernández-Rodríguez R, de Argumedo GL, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G. Fernández-Rodríguez R, et al. J Clin Oncol. 2005 Sep 20;23(27):6797-8; author reply 6798-9. doi: 10.1200/JCO.2005.02.1709. J Clin Oncol. 2005. PMID: 16170190 No abstract available.
• Medical treatment options in patients with metastatic renal cell carcinoma.

  Haferkamp A, Hohenfellner M. Haferkamp A, et al. Nephrol Dial Transplant. 2007 Apr;22(4):996-9. doi: 10.1093/ndt/gfl734. Epub 2007 Jan 8. Nephrol Dial Transplant. 2007. PMID: 17210591 Review. No abstract available.